Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 177

1.

Relationship between circulating serum osteoprotegerin and total receptor activator of nuclear κ-B ligand levels, triglycerides, and coronary calcification in postmenopausal women.

Poornima IG, Mackey RH, Buhari AM, Cauley JA, Matthews KA, Kuller LH.

Menopause. 2014 Jul;21(7):702-10. doi: 10.1097/GME.0000000000000127.

PMID:
24473535
2.

Does osteoprotegerin or receptor activator of nuclear factor-kappaB ligand mediate the association between bone and coronary artery calcification?

Bakhireva LN, Laughlin GA, Bettencourt R, Barrett-Connor E.

J Clin Endocrinol Metab. 2008 May;93(5):2009-12. doi: 10.1210/jc.2007-2624. Epub 2008 Mar 4.

3.

Relationships among serum receptor of nuclear factor-kappaB ligand, osteoprotegerin, high-sensitivity C-reactive protein, and bone mineral density in postmenopausal women: osteoimmunity versus osteoinflammatory.

Nabipour I, Larijani B, Vahdat K, Assadi M, Jafari SM, Ahmadi E, Movahed A, Moradhaseli F, Sanjdideh Z, Obeidi N, Amiri Z.

Menopause. 2009 Sep-Oct;16(5):950-5. doi: 10.1097/gme.0b013e3181a181b8.

PMID:
19387415
4.

Coronary artery calcification and cardiovascular risk: the role of RANKL/OPG signalling.

Quercioli A, Montecucco F, Bertolotto M, Ottonello L, Pende A, Mach F, Dallegri F.

Eur J Clin Invest. 2010 Jul;40(7):645-54. doi: 10.1111/j.1365-2362.2010.02308.x. Epub 2010 May 23. Review.

PMID:
20497460
5.
6.
7.

Serum osteoprotegerin correlates with age and bone mass in postmenopausal, but not in fertile age women.

Mainini G, Incoronato M, Urso L, Scaffa C.

Clin Exp Obstet Gynecol. 2011;38(4):355-9.

PMID:
22268274
8.

Association of genetic polymorphisms of RANK, RANKL and OPG with bone mineral density in Chinese peri- and postmenopausal women.

Shang M, Lin L, Cui H.

Clin Biochem. 2013 Oct;46(15):1493-501. doi: 10.1016/j.clinbiochem.2013.03.011. Epub 2013 Mar 24.

PMID:
23531404
9.

Implications of measuring soluble receptor activators of nuclear factor-kappaB ligand and osteoprotegerin in bone metabolism of elderly women.

Chiba Y, Onouchi T, Ikeda T, Adachi J, Tamura Y, Horiuchi T.

Gerontology. 2009;55(3):275-80. doi: 10.1159/000196280. Epub 2009 Jan 22.

PMID:
19158438
10.

Activation of the receptor activator of the nuclear factor-κB ligand pathway during coronary bypass surgery: comparison between on- and off-pump coronary artery bypass surgery procedures.

Galeone A, Brunetti G, Rotunno C, Oranger A, Colucci S, de Luca Tupputi Schinosa L, Zallone A, Grano M, Paparella D.

Eur J Cardiothorac Surg. 2013 Aug;44(2):e141-7. doi: 10.1093/ejcts/ezt244. Epub 2013 May 12.

PMID:
23671202
12.

Effects of alendronate treatment on serum levels of osteoprotegerin and total receptor activator of nuclear factor kappaB in women with postmenopausal osteoporosis.

Reyes-García R, Muñoz-Torres M, García DF, Mezquita-Raya P, García Salcedo JA, de Dios Luna J.

Menopause. 2010 Jan-Feb;17(1):140-4. doi: 10.1097/gme.0b013e3181ac0cc1.

PMID:
19574937
13.

Osteoprotegerin/RANKL system imbalance in active polyarticular-onset juvenile idiopathic arthritis: a bone damage biomarker?

Spelling P, Bonfá E, Caparbo VF, Pereira RM.

Scand J Rheumatol. 2008 Nov-Dec;37(6):439-44. doi: 10.1080/03009740802116224.

PMID:
18802807
14.

Circulating osteoprotegerin and soluble RANK ligand in systemic sclerosis.

Dovio A, Data V, Carignola R, Calzolari G, Vitetta R, Ventura M, Saba L, Severino A, Angeli A.

J Rheumatol. 2008 Nov;35(11):2206-13. Epub 2008 Oct 1.

PMID:
18843778
15.

Relationships between insulin-like growth factor-I (IGF-I) and OPG, RANKL, bone mineral density in healthy Chinese women.

Zhao HY, Liu JM, Ning G, Zhao YJ, Chen Y, Sun LH, Zhang LZ, Xu MY, Chen JL.

Osteoporos Int. 2008 Feb;19(2):221-6. Epub 2007 Aug 17.

PMID:
17703270
16.

Biomarkers of the osteoprotegerin pathway: clinical correlates, subclinical disease, incident cardiovascular disease, and mortality.

Lieb W, Gona P, Larson MG, Massaro JM, Lipinska I, Keaney JF Jr, Rong J, Corey D, Hoffmann U, Fox CS, Vasan RS, Benjamin EJ, O'Donnell CJ, Kathiresan S.

Arterioscler Thromb Vasc Biol. 2010 Sep;30(9):1849-54. doi: 10.1161/ATVBAHA.109.199661. Epub 2010 May 6.

17.

Circulating osteoprotegerin and receptor activator of NF-kappaB ligand system in patients with beta-thalassemia major.

Angelopoulos NG, Goula A, Katounda E, Rombopoulos G, Kaltzidou V, Kaltsas D, Malaktari S, Athanasiou V, Tolis G.

J Bone Miner Metab. 2007;25(1):60-7. Epub 2007 Jan 1.

PMID:
17187195
18.

CLINICAL Review #: the role of receptor activator of nuclear factor-kappaB (RANK)/RANK ligand/osteoprotegerin: clinical implications.

Vega D, Maalouf NM, Sakhaee K.

J Clin Endocrinol Metab. 2007 Dec;92(12):4514-21. Epub 2007 Sep 25. Review.

PMID:
17895323
19.

The balance between soluble receptors regulating IL-6 trans-signaling is predictive for the RANKL/osteoprotegerin ratio in postmenopausal women with rheumatoid arthritis.

Oelzner P, Franke S, Lehmann G, Eidner T, Hein G, Wolf G.

Rheumatol Int. 2012 Jan;32(1):199-206. doi: 10.1007/s00296-010-1606-z. Epub 2010 Sep 7.

PMID:
20821212
20.

OPG and sRANKL serum levels and incident hip fracture in postmenopausal Caucasian women in the Women's Health Initiative Observational Study.

LaCroix AZ, Jackson RD, Aragaki A, Kooperberg C, Cauley JA, Chen Z, Leboff MS, Duggan D, Wactawski-Wende J.

Bone. 2013 Oct;56(2):474-81. doi: 10.1016/j.bone.2013.05.018. Epub 2013 Jun 2.

Supplemental Content

Support Center